- Home
- TERN vs VIR Comparison
TERN vs VIR Comparison
Compare TERN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- VIR
- Stock Information
- Founded
- TERN 2017
- VIR 2016
- Country
- TERN United States
- VIR United States
- Employees
- TERN N/A
- VIR N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- VIR Health Care
- Exchange
- TERN Nasdaq
- VIR Nasdaq
- Market Cap
- TERN 634.5M
- VIR 706.4M
- IPO Year
- TERN 2021
- VIR 2019
- Fundamental
- Price
- TERN $7.22
- VIR $5.27
- Analyst Decision
- TERN Buy
- VIR Strong Buy
- Analyst Count
- TERN 6
- VIR 10
- Target Price
- TERN $13.99
- VIR $26.80
- AVG Volume (30 Days)
- TERN 1.2M
- VIR 1.6M
- Earning Date
- TERN 08-05-2025
- VIR 10-30-2025
- Dividend Yield
- TERN N/A
- VIR N/A
- EPS Growth
- TERN N/A
- VIR N/A
- EPS
- TERN N/A
- VIR N/A
- Revenue
- TERN N/A
- VIR $19,000,000.00
- Revenue This Year
- TERN N/A
- VIR N/A
- Revenue Next Year
- TERN N/A
- VIR $9.65
- P/E Ratio
- TERN N/A
- VIR N/A
- Revenue Growth
- TERN N/A
- VIR N/A
- 52 Week Low
- TERN $1.87
- VIR $4.16
- 52 Week High
- TERN $11.40
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- TERN 59.36
- VIR 57.10
- Support Level
- TERN $6.78
- VIR $5.04
- Resistance Level
- TERN $7.78
- VIR $5.64
- Average True Range (ATR)
- TERN 0.49
- VIR 0.32
- MACD
- TERN -0.02
- VIR 0.11
- Stochastic Oscillator
- TERN 63.82
- VIR 64.97
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.